Sorry, you need to enable JavaScript to visit this website.

    Pfizer Acquires Polocard, Poland’s Leading Over-The-Counter Heart Attack Prevention Brand

    Continues to Expand Consumer Healthcare Business through Strategic Acquisitions and Partnerships  

    Pfizer Inc. (NYSE: PFE) today announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter (OTC) brand for heart attack prevention in Poland, from ZF Polpharma SA. 
     
    “Polocard is a top OTC brand in Poland, and its acquistion will enhance our Consumer Healthcare portfolio and overall position in this key market,” said Paul Sturman, President, Pfizer Consumer Healthcare.  “We continue to focus on strategic opportunitites that will expand our portfolio of leading brands, develop capabilities in high-growth categories and extend our global reach.”  
     
    The acquisition of Polocard marks the latest of several investments by Pfizer in its Consumer Healthcare business over the last twenty-four months.  Other notable transactions include the exclusive global license agreement with AstraZeneca for the OTC rights for NEXIUM (esomeprazole magnesium) and the acquisitions of Alacer, maker and distributor of Emergen-C products, now the largest selling branded Vitamin C line in the United States, and Ferrosan’s Consumer Healthcare business, which broadened the unit’s industry-leading dietary supplements portfolio as well as its geographic footprint in the Nordics, Russia and Central and Eastern Europe.
     
    The financial terms of the Polocard deal were not disclosed. 
     
    Pfizer Inc.: Working together for a healthier world®
    At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.  We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.  Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.  Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.
    Joan Campion
    (212) 733-2798
    Sign up for the latest Pfizer Wire news alerts

    Receive real-time updates on Pfizer’s news delivered directly to your inbox.

    Our Pipeline: Potential Breakthroughs in the Making

    We're elevating our breakthroughs in a bold new way. Check out our new visualized product pipeline.

    Corporate Fact Sheet

    For more than 170 years, Pfizer has worked to make a difference for all who rely on us.

    Media Asset Library

    Click here to view our media asset library.

    Pfizer Logo

    Our logo is shorthand for everything Pfizer represents: an image that is instantly identifiable to our colleagues, patients, the external scientific community, and the public.

    Executive Leadership

    Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company.

    Stay up to date on the latest news and alerts through the Pfizer Wire

    Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox. 

     

    Sign Up Now